In breast cancer, miR-21 can decrease PTEN and PDCD4 expression, whereas treatment with a miR-21 inhibitor combined with trastuzumab [38] or doxorubicin [39] can restore drug sensitivity. This evidence concerns the gene PDCD4 and breast cancer.